Das 1805 gegründete Universitätsklinikum Tübingen ist das Klinikum der Universität Tübingen. Gemeinsam mit der medizinischen Fakultät der Universität. Die Einrichtungen des Universitätsklinikums Tübingen sind überwiegend auf zwei Klinikareale verteilt.

During the past decade, Universitätsklinikum Tübingen conducted 261 clinical trials. In the 10-year time frame, 261 clinical trials started and 88 clinical trials were completed, i.e. on average, 33.7% percent of trials that started reached the finish line to date. In the past 5 years, 117 clinical trials started and 68 clinical trials were completed. i.e. 58.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitätsklinikum Tübingen" #1 sponsor was "Janssen Research & Development, LLC" with 18 trials, followed by "Hoffmann-La Roche" with 16 trials sponsored, "Boehringer Ingelheim" with 14 trials sponsored, "Celgene" with 13 trials sponsored and "Pfizer" with 13 trials sponsored. Other sponsors include 297 different institutions and companies that sponsored additional 167 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsklinikum Tübingen" #1 collaborator was "Merck Sharp & Dohme LLC" with 7 trials as a collaborator, "University Hospital Tuebingen" with 7 trials as a collaborator, "German Research Foundation" with 6 trials as a collaborator, "Hoffmann-La Roche" with 5 trials as a collaborator and "Novartis Pharmaceuticals" with 5 trials as a collaborator. Other collaborators include 285 different institutions and companies that were collaborators in the rest 235 trials.

According to Clinical.Site data, the most researched conditions in "Universitätsklinikum Tübingen" are "Multiple Myeloma" (15 trials), "Acute Myeloid Leukemia" (10 trials), "Ovarian Cancer" (9 trials), "Atrial Fibrillation" (8 trials) and "Melanoma" (8 trials). Many other conditions were trialed in "Universitätsklinikum Tübingen" in a lesser frequency.

Most popular intervention types in "Universitätsklinikum Tübingen" are "Drug" (270 trials), "Device" (47 trials), "Biological" (45 trials), "Other" (36 trials) and "Procedure" (26 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (66 trials), "Dexamethasone" (15 trials), "radiation therapy" (11 trials), "Pomalidomide" (8 trials) and "Bortezomib" (7 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinikum Tübingen" are 337 trials for "All" genders, 26 trials for "Female" genders and 13 trials for "Male" genders.

Currently, there are 154 active trials in "Universitätsklinikum Tübingen". 2 are not yet recruiting, 90 are recruiting, 61 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 162 completed trials in Universitätsklinikum Tübingen, 1 suspended trials, and 35 terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinikum Tübingen, 23 "Phase 1" clinical trials were conducted, 117 "Phase 2" clinical trials and 161 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 14 trials, and there were also 39 trials that are defined as “Not Applicable".